Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 762

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 762
---
 employment terminates with the Company.

Proposed Merger

On October 4, 2024,
at the Company’s Special Meeting of Stockholders, the Company’s stockholders approved the requisite proposals to effect the completion of the proposed Merger with TuHURA. The proposed Merger is expected to be consummated in mid-October 2024, subject to regulatory approval and the satisfaction of the remaining closing conditions under the Merger Agreement.

F-29

Kintara Therapeutics, Inc. Condensed Consolidated Interim Balance Sheets (In thousands, except par value amounts)

|                                                                                   |     |      |     | September, 
 2024       |          |   |     | June 30, 
 2024     |          |   |
|:----------------------------------------------------------------------------------|:----|-----:|:----|:-----------|---------:|:--|:----|:---------|---------:|:--|
|                                                                                   |     | Note |     | $          |          |   |     | $        |          |   |
|                                                                                   |     |      |     | -unaudited |          |   |     |          |          |   |
| Assets                                                                            |     |      |     |            |          |   |     |          |          |   |
| Current assets                                                                    |     |      |     |            |          |   |     |          |          |   |
| Cash and cash equivalents                                                         |     |      |     |            |    3,020 |   |     |          |    4,909 |   |
| Prepaid expenses, taxes and other receivables                                     |     |      |     |            |      258 |   |     |          |      414 |   |
| Clinical trial deposit                                                            |     |    3 |     |            |      205 |   |     |          |      205 |   |
| Total current assets                                                              |     |      |     |            |    3,483 |   |     |          |    5,528 |   |
| Property and equipment, net                                                       |     |    5 |     |            |      657 |   |     |          |      674 |   |
| Total assets                                                                      |     |      |     |            |    4,140 |   |     |          |    6,202 |   |
| Liabilities                                                                       |     |      |     |            |